Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | CASP2 | P42575 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.30 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18736144 | 0.79 | TSHR (0.40) | SLC6A5TSHRHDAC6PAOXCASP2 | |
| SCHEMBL23774416 | 0.79 | CASP2 (0.36) | TSHRCASP2SMN1; SMN2 | |
| SCHEMBL18666285 | 0.78 | TSHR (0.48) | SLC6A5TSHRPAOXCASP2SMN1; SMN2 | |
| SCHEMBL14978144 | 0.76 | TSHR (0.42) | SLC6A5TSHRHDAC6PAOXCASP2 | |
| SCHEMBL18653329 | 0.75 | SLC6A5 (0.39) | SLC6A5TSHRCASP2SMN1; SMN2KDM4A | |
| SCHEMBL24383343 | 0.75 | SLC6A5 (0.39) | SLC6A5TSHRHDAC6PAOXKDM4A | |
| SCHEMBL23723856 | 0.75 | TSHR (0.36) | SLC6A5TSHRHDAC6PAOXSMN1; SMN2 | |
| SCHEMBL23969137 | 0.74 | HDAC6 (0.36) | SLC6A5TSHRHDAC6PAOXMAOA | |
| SCHEMBL13785356 | 0.74 | TSHR (0.40) | SLC6A5TSHRHDAC6PAOXCASP2 | |
| SCHEMBL15160283 | 0.74 | SLC6A5 (0.38) | SLC6A5TSHRPAOXCASP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | SLC6A5 4195/4885TSHR 3308/4885HDAC6 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.